Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Leveraging long-read RNA-sequencing to understand the pathophysiology of familial and complex Alzheimer’s disease

Project description

Uncovering Alzheimer’s disease mechanisms through RNA sequencing

Alzheimer’s disease is a leading neurodegenerative disorder with complex genetic and molecular origins that are still not fully understood, particularly in its familial and early-onset forms. Supported by the Marie Skłodowska-Curie Actions programme, the TranscriptAccuracyAD project will use long-read RNA sequencing to investigate how specific mutations in the PSEN1 gene compare between mutant and corrected cell lines to identify disease-related transcriptional changes and shared mechanisms with sporadic Alzheimer’s. The project will further integrate advanced computational analyses and cross-dataset comparisons to map disrupted pathways and explore potential RNA-based therapeutic targets. Overall, the project deepens understanding of Alzheimer’s disease at the molecular level and supports the development of novel, mechanism-based therapeutic strategies.

Objective

Mutations in Presenilin 1 (PSEN1) represent the most common cause of autosomal dominant familial Alzheimer’s disease (fAD), resulting in a severe early-onset phenotype. Two pathogenic PSEN1 variants, the intron 4 deletion (int4del) and the missense mutation R278I, have been associated with fAD. However, their transcriptional consequences remain remarkably understudied.

I hypothesise that int4del and R278I (i) perturb PSEN1 splicing, thereby compromising diverse PSEN1 functions in neuronal pathways that are central to Alzheimer’s pathogenesis, with the potential to exacerbate pathology; and (ii) can reveal molecular mechanisms shared with sporadic forms of the disease, paving the way for novel therapeutic strategies.

To test this hypothesis, I propose analysing a novel long-read RNA-sequencing dataset formed by 12 induced pluripotent stem cell (iPSC)-derived samples from two fAD patients. These include triplicate neuronal lines harbouring the int4del and R278I mutations, respectively, alongside isogenic CRISPR-Cas9-corrected controls. Using cutting-edge techniques developed at Prof. Ana Conesa’s lab (I2SysBio, Valencia, Spain), I will: (i) characterise the complex transcriptional landscape associated with each mutation; (ii) predict the disruption of cis-acting regulators and related consequences on transcript structure; (iii) evaluate downstream cellular pathways compromised by altered transcripts; and (iv) cross-evaluate the fAD transcriptional signatures detected against published datasets from sporadic AD (sAD) patients. During my secondment at the Institute of Neurosciences (Alicante, Spain), I will be excellently trained in wet-lab assays to acquire practical skills in shRNA delivery and cell line manipulation within the context of neurodegeneration.

This work will provide critical insights into the transcriptional mechanisms underlying fAD pathogenesis, aiming to inform the identification of novel RNA therapeutic strategies with applications in sAD.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2025-PF

See all projects funded under this call

Coordinator

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Net EU contribution
€ 194 074,56
Address
CALLE SERRANO 117
28006 Madrid
Spain
Region
Comunidad de Madrid Comunidad de Madrid Madrid
Activity type
Research Organisations
Links
Total cost
No data